Wolfgang Miesbach: Modern Hemophilia Therapies and the Challenges of Laboratory Monitoring
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared post on LinkedIn about a recent article he and his colleagues co-authored, published in Transfusion Medicine and Hemotherapy, adding:
“Excited to share our new open-access review in Transfusion Medicine and Hemotherapy!
From EHL factor concentrates and FVIII-mimetic antibodies to gene therapies and rebalancing agents, we have more tools than ever to improve prophylaxis and patient outcomes.
However, these therapeutic breakthroughs also introduce profound analytical challenges for our laboratories.
Conventional coagulation assays were designed for standard replacement therapies.
Today, applying them to modified molecules or non-factor therapies requires careful navigation:
Non-Factor Interferences: FVIII-mimetics (like emicizumab) artificially shorten aPTT-based tests, rendering them unreliable without specific adaptations. Meanwhile, rebalancing therapies (like fitusiran or anti-TFPIs) require entirely new monitoring paradigms.
Gene Therapy Discrepancies: Transgene-derived FVIII and FIX variants often show systematic, assay-dependent discrepancies between one-stage clotting assays (OSCA) and chromogenic substrate assays (CSA). Consistent longitudinal monitoring strategies are absolutely essential for accurate follow-up.
The Role of TGAs: Global hemostatic assays, particularly Thrombin Generation Assays (TGAs), hold immense promise for the integrative assessment of a patient’s coagulation potential. However, standardization remains a hurdle we must overcome as a community.
As clinicians and researchers, close communication with our specialized hemostasis laboratories is no longer just helpful—it is critical to avoid misinterpreting data and to ensure optimal patient care.”
Tiltle: Laboratory Challenges in the Era of Novel Haemophilia Therapies.
Authors: Heiko Rühl, Wolfgang Miesbach and Jens Müller
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 28, 2026, 09:45Emma Groarke: The 3rd International VEXAS Conference in Milan
-
Sep 28, 2026, 09:36Iman Alshamsi: Thrombophilia Workup and PNH Screening When Testing Matters
-
Sep 28, 2026, 09:25Emadullah Raidullah: Thrombophilia Workup and PNH Screening When Testing Matters
-
Sep 28, 2026, 03:59Rahul Saha: JAMA The 49th Human Blood Group System
-
Sep 28, 2026, 01:51Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead
-
Sep 27, 2026, 15:49Rana Al-Hrout: Iron Deficency – Is Ferritin 15ng/mL or Less Still the Cutoff?
-
Sep 27, 2026, 15:49Ayushi Sharma: What I Thought Transfusion Medicine Would Be vs What It Actually Is
-
Sep 27, 2026, 15:48William Wallace: How Much Human Research Is Behind the Supplements We Take?
-
Sep 27, 2026, 15:46Franck Perraudin: Lp(a) Lowering Alone May Not Be Enough